Agenus :: the patient is waiting
The patient is waiting
- Home
- Media
Our expertise with cancer vaccines and heat shock proteins, and QS-21 Stimulon® adjuvant, continues to be validated and supported as our products advance through the clinic and enjoy newsworthy successes.
Press releases
2012
Agenus Reports First Quarter 2012 Financial Results and Corporate Updates
April 25, 2012
Agenus to Report First Quarter Financial Results on April 25, 2012; Conference Call to Follow
April 19, 2012
New Phase 2 Data from Brain Cancer Study with Agenus’ Prophage Vaccine (HSPPC-96) Presented at Plenary Session of AANS
April 17, 2012
Shalini Sharp Transitions to Agenus' Board of Directors
March 20, 2012
Agenus Reports Fourth Quarter and Year End 2011 Financial Results and Corporate Update
March 5, 2012
Agenus Expands QS-21 License and Grants Right of First Negotiation to GlaxoSmithKline
March 5, 2012
Agenus to Present at the 2012 Cowen Health Care Conference
March 1, 2012
Agenus to Report Fourth Quarter and Year-End 2011 Financial Results on March 5, 2012; Conference Call to Follow
February 29, 2012
Agenus to Present at BIO CEO & Investor Conference
February 6, 2012
Agenus to Present at OneMedForum San Francisco 2012
January 4, 2012
2011
Agenus and ChemRar Enter into Agreement in the Area of Personalized Cancer Vaccines
December 19, 2011
Agenus Vaccine for Brain Cancer Highlighted at Current State of the Art Session at the Annual Society for Neuro-Oncology (SNO) Meeting
November 16, 2011
Agenus Reports Third Quarter 2011 Financial Results and Corporate Updates
October 27, 2011
Agenus to Report Third Quarter Financial Results on October 27, 2011; Conference Call to Follow
October 20, 2011
Positive Results Shown with Agenus' QS-21 Stimulon® adjuvant in Phase 3 trial of GlaxoSmithKline's Malaria Vaccine
October 18, 2011
Agenus to Present at NewsMakers in the Biotech Industry Conference
October 18, 2011
Agenus Compliant with NASDAQ Listing Requirements
October 17, 2011
Agenus Announces Stock Symbol to Revert Back to AGEN
October 11, 2011
Agenus to Present at Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
October 3, 2011
Agenus Announces Reverse Stock Split
September 30, 2011
Clinical Data Published in Vaccine Demonstrate Robust Immune Response with Agenus’ Herpes Vaccine Containing QS-21 Adjuvant
September 26, 2011
Agenus to Present at JMP Securities Healthcare Conference
September 22, 2011
Agenus Prices At Market Underwritten Offering of Common Stock
August 11, 2011
Agenus Reports Second Quarter 2011 Financial Results and Corporate Updates
July 28, 2011
Agenus to Report Second Quarter Financial Results on July 28, 2011; Conference Call to Follow
July 21, 2011
Agenus’ Herpes Study Results Presented at BIO International Convention Show Robust Immune Response
June 27, 2011
Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons
A heat shock protein based polyvalent vaccine targeting HSV-2: CD4+ and CD8+ cellular immunity and protective efficacy
Agenus’ QS-21 Stimulon® Adjuvant Selected for Biodefense Program
June 14, 2011
New Data from Phase 2 Brain Cancer Study with Prophage Series G-200 (HSPPC-96) Shows Improved Overall Survival
June 6, 2011
Agenus to Webcast 2011 Annual Shareholders Meeting
June 1, 2011
Agenus Announces Investor Briefing at the American Society of Clinical Oncology (ASCO) 2011 Chicago Meeting
May 24, 2011
Agenus Reports First Quarter 2011 Financial Results
April 28, 2011
Agenus to Report First Quarter Financial Results on April 28, 2011; Conference Call to Follow
April 21, 2011
News and Highlights From Around the Web
December 2, 2011: Neuroscene.com
Neuroscene.com Podcast Profiles ACC-001, Which Contains Agenus QS-21 Vaccine Adjuvant"One of the most promising areas of Alzheimer’s disease research involves vaccine-based therapies which stimulate the body to produce antibodies to amyloid-beta protein and remove it from the brain. And despite setbacks in previous clinical trials, scientists are currently working on second-generation vaccines that seem to reverse the cognitive deficits of Alzheimer’s disease without the side effects of the first-generation therapies.
In this podcast, we speak with Dr. Gene Kinney of Janssen Alzheimer Immunotherapy and Dr. Michael Hagen of Pfizer Pharmaceuticals. Dr. Kinney and Dr. Hagan are involved with the research and development of ACC-001, one of the most advanced second-generation vaccine-based therapies under development."
September, 2011: Minyanville.com
Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution